Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Dow
Julphar
McKesson
Chubb
Boehringer Ingelheim
Healthtrust
Accenture
US Army

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,980,881

« Back to Dashboard

Summary for Patent: 8,980,881
Title:Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Abstract: The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same and uses thereof.
Inventor(s): Agarwal; Rajesh K. (San Diego, CA), Betts, III; William L. (San Diego, CA), Henshilwood; James A. (Carlsbad, CA), Kiang; Yuan-Hon (Newbury Park, CA), Post; Noah (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/616,887
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,980,881
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,980,881

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,980,881

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,168,624 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride ➤ Try a Free Trial
8,697,686 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,980,881

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 442359 ➤ Try a Free Trial
Australia 2005318959 ➤ Try a Free Trial
Brazil PI0519726 ➤ Try a Free Trial
Canada 2589988 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
UBS
QuintilesIMS
Healthtrust
Chubb
Cerilliant
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.